TY - JOUR
T1 - Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease
AU - The BODE Collaborative Group
AU - Divo, Miguel J.
AU - Marin, José M.
AU - Casanova, Ciro
AU - Cabrera Lopez, Carlos
AU - Pinto-Plata, Victor M.
AU - Marin-Oto, Marta
AU - Polverino, Francesca
AU - de-Torres, Juan P.
AU - Billheimer, Dean
AU - Celli, Bartolome R.
AU - Celli, Bartolome R.
AU - Marin, José M.
AU - Macario, Ciro Casanova
AU - Pinto-Plata, Victor
AU - de-Torres, Juan Pablo
AU - Divo, Miguel J.
AU - Lopez, Carlos Cabrera
AU - Polverino, Francesca
AU - Oto, Marta Marin
N1 - Funding Information: Miguel J. Divo, José M. Marin, Ciro Casanova Macario, Carlos Cabrera Lopez, Victor M. Pinto-Plata, Marta Marin-Oto, Francesca Polverino, Juan P. de-Torres, and Bartolome R. Celli, are the members of the BODE Collaborative Group. Consortia The BODE Collaborative Group members: Bartolome R. Celli, MD—Pulmonary and Critical Care Division, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115, USA. bcelli@copdnet.org. Jose M. Marin, MD—Respiratory Service, Hospital Universitario Miguel Servet-IISAragón & CIBER Enfermedades Respiratorias; Avda Isabel la Catolica 1-3, Zaragoza 50006, Spain. jmmarint@unizar.es. Ciro Casanova, MD—Pulmonary Department, Hospital Universitario La Candelaria, Universidad de La Laguna, Carretera del Rosario n 145, 38010-Santa Cruz de Tenerife, Spain. casanovaciro@gmail.com. Victor Pinto-Plata, MD—Pulmonary and Critical Care Division Chair, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA. victor.m.pinto-plata@lahey.org. Juan Pablo de-Torres, MD—Division of Respirology and Sleep Medicine, Queen's University, Kingston, Canada. j.detorrestajes@queensu.ca. Miguel J. Divo, MD MPH—Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, Massachusetts 02115, USA. mdivo@bwh.harvard.edu. Carlos Cabrera Lopez, MD—Respiratory Service, Hospital Universitario de Gran Canaria Dr. Negrin, Canary Islands, Spain. ccablopn@gmail.com. Francesca Polverino, MD Ph.D.—Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. francesca.polverino@bcm.edu. Marta Marin Oto, MD—Pulmonary Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. marta.marin.oto@gmail.com Funding Information: Partial funding for this study was provided by an unrestricted grant from the Clinical Research Foundation. Publisher Copyright: © 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Rationale and objective: Patients with chronic obstructive pulmonary disease (COPD), usually diagnosed after the 6th decade, frequently suffer from comorbidities. Whether COPD patients 50 years or younger (Young COPD) have similar comorbidities with the same frequency and mortality impact as aged-matched controls or older COPD patients is unknown. Methods: We compared comorbidity number, prevalence and type in 3 groups of individuals with ≥ 10 pack-years of smoking: A Young (≤ 50 years) COPD group (n = 160), an age-balanced control group without airflow obstruction (n = 125), and Old (> 50 years) COPD group (n = 1860). We also compared survival between the young COPD and control subjects. Using Cox proportional model, we determined the comorbidities associated with mortality risk and generated Comorbidomes for the “Young” and “Old” COPD groups. Results: The severity distribution by GOLD spirometric stages and BODE quartiles were similar between Young and Old COPD groups. After adjusting for age, sex, and pack-years, the prevalence of subjects with at least one comorbidity was 31% for controls, 77% for the Young, and 86% for older COPD patients. Compared to controls, “Young” COPDs’ had a nine-fold increased mortality risk (p < 0.0001). “Comorbidomes” differed between Young and Old COPD groups, with tuberculosis, substance use, and bipolar disorders being distinct comorbidities associated with increased mortality risk in the Young COPD group. Conclusions: Young COPD patients carry a higher comorbidity prevalence and mortality risk compared to non-obstructed control subjects. Young COPD differed from older COPD patients by the behavioral-related comorbidities that increase their risk of premature death.
AB - Rationale and objective: Patients with chronic obstructive pulmonary disease (COPD), usually diagnosed after the 6th decade, frequently suffer from comorbidities. Whether COPD patients 50 years or younger (Young COPD) have similar comorbidities with the same frequency and mortality impact as aged-matched controls or older COPD patients is unknown. Methods: We compared comorbidity number, prevalence and type in 3 groups of individuals with ≥ 10 pack-years of smoking: A Young (≤ 50 years) COPD group (n = 160), an age-balanced control group without airflow obstruction (n = 125), and Old (> 50 years) COPD group (n = 1860). We also compared survival between the young COPD and control subjects. Using Cox proportional model, we determined the comorbidities associated with mortality risk and generated Comorbidomes for the “Young” and “Old” COPD groups. Results: The severity distribution by GOLD spirometric stages and BODE quartiles were similar between Young and Old COPD groups. After adjusting for age, sex, and pack-years, the prevalence of subjects with at least one comorbidity was 31% for controls, 77% for the Young, and 86% for older COPD patients. Compared to controls, “Young” COPDs’ had a nine-fold increased mortality risk (p < 0.0001). “Comorbidomes” differed between Young and Old COPD groups, with tuberculosis, substance use, and bipolar disorders being distinct comorbidities associated with increased mortality risk in the Young COPD group. Conclusions: Young COPD patients carry a higher comorbidity prevalence and mortality risk compared to non-obstructed control subjects. Young COPD differed from older COPD patients by the behavioral-related comorbidities that increase their risk of premature death.
KW - COPD in the young
KW - Comorbidities
UR - http://www.scopus.com/inward/record.url?scp=85138896403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138896403&partnerID=8YFLogxK
U2 - https://doi.org/10.1186/s12931-022-02191-7
DO - https://doi.org/10.1186/s12931-022-02191-7
M3 - Article
C2 - 36167533
SN - 1465-9921
VL - 23
JO - Respiratory Research
JF - Respiratory Research
IS - 1
M1 - 267
ER -